Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA Fusion-Positive From Other Central Nervous System Tumors

L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA... J Neuropathol Exp Neurol Vol. 81, No. 1, January 2022, pp. 82–85 doi: 10.1093/jnen/nlab105 LETTER TO THE EDITOR L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA Fusion-Positive From Other Central Nervous System Tumors 1 1 1 1 1 Oumaima Aboubakr, MS, Alice Metais, MD, Charlotte Berthaud, Priscille Gigant, Leı¨la Mehdi, 1 1 1 1,2 Noemie Pucelle, Joelle Lacombe, Lauren Hasty, Fabrice Chretien, MD, PhD, 1,2 1,2,3 1,2,3 Emmanue`le Lechapt, MD, PhD, Pascale Varlet, MD, PhD, and Arnault Tauzie`de-Espariat, MD Department of Neuropathology, GHU Paris-Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France Universite de Paris, Paris, France Institute of Psychiatry and Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France Correspondence to: Arnault Tauzie`de-Espariat, Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014 Paris, France; E-mail: [email protected] in other studies, using 3 different methods as follows: method To the Editor: 1, positivity for >1% immunostained cells with cytoplasmic In 2016, the ependymoma, RELA fusion-positive or membranous staining (4); method 2, positivity for >10% (mainly with the C11orf95 gene, now called ZFTA), was in- tumor cells with membranous staining (1); and method 3, troduced into The World Health Organization (WHO) Classi- positivity for >50% tumor http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Neuropathology & Experimental Neurology Oxford University Press

L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA Fusion-Positive From Other Central Nervous System Tumors

Download PDF
4 pages

Loading next page...
 
/lp/oxford-university-press/l1cam-is-not-a-reliable-diagnostic-biomarker-for-distinguishing-toHErqRLxM

References (6)

Publisher
Oxford University Press
Copyright
© 2022 American Association of Neuropathologists, Inc. All rights reserved.
ISSN
0022-3069
eISSN
1554-6578
DOI
10.1093/jnen/nlab105
Publisher site
See Article on Publisher Site

Abstract

J Neuropathol Exp Neurol Vol. 81, No. 1, January 2022, pp. 82–85 doi: 10.1093/jnen/nlab105 LETTER TO THE EDITOR L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA Fusion-Positive From Other Central Nervous System Tumors 1 1 1 1 1 Oumaima Aboubakr, MS, Alice Metais, MD, Charlotte Berthaud, Priscille Gigant, Leı¨la Mehdi, 1 1 1 1,2 Noemie Pucelle, Joelle Lacombe, Lauren Hasty, Fabrice Chretien, MD, PhD, 1,2 1,2,3 1,2,3 Emmanue`le Lechapt, MD, PhD, Pascale Varlet, MD, PhD, and Arnault Tauzie`de-Espariat, MD Department of Neuropathology, GHU Paris-Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France Universite de Paris, Paris, France Institute of Psychiatry and Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France Correspondence to: Arnault Tauzie`de-Espariat, Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014 Paris, France; E-mail: [email protected] in other studies, using 3 different methods as follows: method To the Editor: 1, positivity for >1% immunostained cells with cytoplasmic In 2016, the ependymoma, RELA fusion-positive or membranous staining (4); method 2, positivity for >10% (mainly with the C11orf95 gene, now called ZFTA), was in- tumor cells with membranous staining (1); and method 3, troduced into The World Health Organization (WHO) Classi- positivity for >50% tumor

Journal

Journal of Neuropathology & Experimental Neurology – Oxford University Press

Published: Jan 21, 2022

There are no references for this article.